DOCTIS has organized a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. This event will be held on the 7th of October 2021, free of charge, online and will start at 5 p.m CET, sponsored by IMIDomics.
DOCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches” aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and psoriatic arthritis.
Despite major advances in the molecular and cellular characterization of common diseases, there has been a steady decline of new effective therapies. Also within approved drugs, significant clinical efficacy is only observed in a subset of patients. Combination therapies could be a useful strategy to overcome this major medical problem. This virtual symposium will be a venue to share insights on the clinical and translational challenges of discovering and implementing combination therapies in common diseases.
Agenda of the DOCTIS symposium
17:00 – 17:10: Welcome by Sara Marsal, coordinator of the DOCTIS project and Head of Rheumatology Department in Vall d’Hebron Hospital Campus, Barcelona, Spain.
The first block of presentations: Clinical Challenges. Moderated by Sara Marsal.
17:10 – 17:30: ‘Precision Medicine in Advanced Breast Cancer. – Cristina Saura, Head of Breast Cancer Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain
17:30 – 17:50: ‘Combination strategies in IBD: opportunity or challenge?’ – Bram Verstockt, clinician-scientist at the Gastroenterology-Hepatology Department at the University Hospitals Leuven, Belgium
17:50 – 18:10: ‘Designing Adaptive Clinical Trials for Combination Therapies in Type 1 Diabetes’ – Adrian Mander, Director of Statistics at the Centre for Trials Research in Cardiff University, UK.
18:10 – 18:25: Q&A
The second block of presentations: Translational challenges. Moderated by Antonio Julià, Head of Rheumatology Research Group in Vall d’Hebron Hospital Campus, Barcelona, Spain.
18:30 – 18:50: ‘Combining high-throughput perturbation experiments and mathematical modeling to identify efficacious combinations’ – Julio Saez–Rodriguez, Head of Systems Biomedicine Group, Heidelberg University, Germany.
18:50 – 19:10: ‘Leveraging multi-modal single-cell atlases to predict perturbations’ – Mohammad Lotfollahi, Institute of Computational Biology, Helmholtz Zentrum München, Germany.
19:10 – 19:30: ‘Network-based prediction of drug combinations’ – István Kovács, Head of Kovacs Labs: Complex Systems, Northwestern University, Evanston, USA.
19:30 – 19:45: Q&A
19:45-19:50: Closing by Sara Marsal, coordinator of the DOCTIS project and Head of Rheumatology Department in Vall d’Hebron Hospital Campus, Barcelona